Drug development for use during pregnancy: Impact of the placenta

Expert Review of Obstetrics and Gynecology

Volumn 5, Issue 4, 2010, Pages 437-454

  Malek, Antoine ^a   Mattison, Donald R ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

developmental toxicity; drug development; efficacy; obstetrics; pharmacodynamics; pharmacokinetics; placenta; safety

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; CARRIER PROTEIN; HEPARIN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INFLUENZA VACCINE; LABETALOL; LOW MOLECULAR WEIGHT HEPARIN; METHYLDOPA; NANOMATERIAL; NIFEDIPINE; PROPYLTHIOURACIL; THIAMAZOLE; WARFARIN;

ACTIVE TRANSPORT; BLOOD PLACENTA BARRIER; CARDIOVASCULAR SYSTEM; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ENDOCYTOSIS; EXOCYTOSIS; FETUS CIRCULATION; GASTROINTESTINAL TRACT; HUMAN; HYPERTHYROIDISM; INFLUENZA; MALARIA; MATERNAL BLOOD; MATERNAL HYPERTENSION; MEMBRANE VESICLE; PASSIVE TRANSPORT; PLACENTA; PLACENTA FUNCTION; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; RESPIRATORY SYSTEM; REVIEW; UROGENITAL SYSTEM; VENOUS THROMBOEMBOLISM;

EID: 77954463009     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.10.29     Document Type: Review

References (296)

1. Sneader W. Drug Discovery: a History. Wiley, NJ, USA (2005).
2. Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 372(9643), 1073-1087 (2008).
3. Hai CM. Mechanistic systems biology of inflammatory gene expression in airway smooth muscle as tool for asthma drug development. Curr. Drug. Discov. Technol. 5(4), 279-288 (2008).
4. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J. Health Econ. 22(2), 151-185 (2003).
5. Shah S, Van Geijn H. Managing the risks of off-licence prescribing in pregnancy. Eur. J. Obstet. Gynecol. 130, 156-159 (2007).
6. Vernon JA, Golec JH, Dimasi JA. Drug development costs when financial risk is measured using the Fama-French three-factor model. Health Econ. DOI: 10.1002/ hec.1538 (2009) (Epub ahead of print).
7. Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta 27(8), 861-868 (2006).
8. Ward RM. Drug therapy of the fetus. J. Clin. Pharmacol. 33(9), 780-789 (1993).
9. Brabin BJ, Romagosa C, Abdelgalil S et al. The sick placenta - the role of malaria. Placenta 25(5), 359-378 (2004).
10. Hawcutt DB, Smyth RL. Drug development for children: how is pharma tackling an unmet need? IDrugs 11(7), 502-507 (2008).
11. Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin. Ther. 30(11), 2133-2145 (2008).
12. Kapogiannis BG, Mattison DR. Adolescents in clinical trials. Clin. Pharmacol. Ther. 84(6), 655-659 (2008).
13. Little BB. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet. Gynecol. 93(5 Pt 2), 858-868 (1999).
14. Barbour V, Clark J, Peiperl L, Veitch E, Wong M, Yamey G. Drug development for maternal health cannot be left to the whims of the market. PLoS Med. 5(6), e140 (2008).
15. Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med. 5(1), e22 (2008).
16. White NJ, McGready RM, Nosten FH. New medicines for tropical diseases in pregnancy: catch-22. PLoS Med. 5(6), e133 (2008).
17. Chervenak FA, McCullough LB. Women and children first: transforming a historic defining moment into a contemporary ethical imperative. Am. J. Obstet. Gynecol. 201(4), 351.e351-e355 (2009).
18. DiMasi JA, Paquette C. The economics of follow-on drug research and development: trends in entry rates and the timing of development. Pharmacoeconomics 22(2 Suppl. 2), 1-14 (2004).
19. Rayburn WF. A physician's prerogative to prescribe drugs for off-label uses during pregnancy. Obstet. Gynecol. 81(6), 1052-1055 (1993).
20. Rayburn WF, Farmer KC. Off-label prescribing during pregnancy. Obstet. Gynecol. Clin. North Am. 24(3), 471-478 (1997).
21. Dresser R, Frader J. Off-label prescribing: a call for heightened professional and government oversight. J. Law Med. Ethics 37(3), 476-486, 396 (2009).
22. Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch. Intern. Med. 169(19), 1745-1747 (2009).
23. Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 462(7270), 175-181 (2009).
24. Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 22(2), 119-125 (2009).
25. Mattison DR, Blann E, Malek A. Physiological alterations during pregnancy: impact on toxicokinetics. Fundam. Appl. Toxicol. 16(2), 215-218 (1991).
26. Granger JP. Maternal and fetal adaptations during pregnancy: lessons in regulatory and integrative physiology. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283(6), R1289-R1292 (2002).
27. Chesnutt AN. Physiology of normal pregnancy. Crit. Care Clin. 20(4), 609-615 (2004).
28. Norwitz ER, Edusa V, Park JS. Maternal physiology and complications of multiple pregnancy. Semin. Perinatol. 29(5), 338-348 (2005).
29. Lee LK. Physiological adaptations of pregnancy affecting the nervous system. Semin. Neurol. 27(5), 405-410 (2007).
30. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr. Drug Metab. 10(5), 520-529 (2009).
31. Weier N, He SM, Li XT, Wang LL, Zhou SF. Placental drug disposition and its clinical implications. Curr. Drug Metab. 9(2), 106-121 (2008).
32. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am. J. Gastroenterol. 104(1), 228-233 (2009).
33. Myllynen P, Immonen E, Kummu M, Vähäkangas K. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opin. Drug Metab. Toxicol. 5(12), 1483-1499 (2009).
34. Sölder E, Rohr I, Kremser C, Hutzler P, Debbage PL. Imaging of placental transport mechanisms: a review. Eur. J. Obstet. Gynecol. Reprod. Biol. 144(Suppl. 1), S114-S120 (2009).
35. Andrade SE, Gurwitz JH, Davis RL et al. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol. 191(2), 398-407 (2004).
36. Lee E, Maneno MK, Smith L et al. National patterns of medication use during pregnancy. Pharmacoepidemiol. Drug Saf. 15(8), 537-545 (2006).
37. Engeland A, Bramness JG, Daltveit AK, Rønning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. Br. J. Clin. Pharmacol. 65(5), 653-660 (2008).
38. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol. Drug Saf. 18(3), 211-225 (2009).
39. Kebede B, Gedif T, Getachew A. Assessment of drug use among pregnant women in Addis Ababa, Ethiopia. Pharmacoepidemiol. Drug Saf. 18(6), 462-468 (2009).
40. Viktil KK, Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population-based cohort study. Pharmacoepidemiol. Drug Saf. 18(8), 737-742 (2009).
41. Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: a population-based study in Regione Emilia-Romagna, Italy. Eur. J. Clin. Pharmacol. 64, 1125-1132 (2008).
42. Schardein JL. Chemically Induced Birth Defects. Marcel Dekker, NY, USA (2000).
43. Drugs During Pregnancy and Lactation. Treatment Options and Risk Assessment (2nd Edition). Schaefer C, Peters P, Miller RK (Eds). Elsevier, Amsterdam, The Netherlands (2007).
44. Shepard TH, Lemire RJ. Catalog of Teratogenic Agents. Johns Hopkins University Press, MD, USA (2007).
45. Sabath LD, Philipson A, Charles D. Ethics and the use of drugs during pregnancy. Science 202(4367), 540-541 (1978).
46. Chervenak FA, McCullough LB. A comprehensive ethical framework for fetal research and its application to fetal surgery for spina bifida. Am. J. Obstet. Gynecol. 187(1), 10-14 (2002).
47. Chervenak FA, McCullough LB, Birnbach DJ. Ethical issues in fetal surgery research. Best Pract. Res. Clin. Anaesthesiol. 18(2), 221-230 (2004).
48. Chervenak FA, McCullough LB. Ethics of maternal-fetal surgery. Semin. Fetal Neonatal Med. 12(6), 426-431 (2007).
49. Kilama WL. Ethical perspective on malaria research for Africa. Acta Trop. 95(3), 276-284 (2005).
50. Anger GJ, Piquette-Miller M. Pharmacokinetic studies in pregnant women. Clin. Pharmacol. Ther. 83(1), 184-187 (2008).
51. Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract. Res. Clin. Obstet. Gynaecol. 15(6), 819-826 (2001).
52. Ellegard EK. Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin. Rev. Allergy Immunol. 26(3), 149-159 (2004).
53. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44(10), 989-1008 (2005).
54. Muallem MM, Rubeiz NG. Physiological and biological skin changes in pregnancy. Clin. Dermatol. 24, 80-83 (2006).
55. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin. Drug Metab. Toxicol. 3(4), 557-571 (2007).
56. Hill CC, Pickinpaugh J. Physiologic changes in pregnancy. Surg. Clin. N. Am. 88, 391-401 (2008).
57. Chunilal SD, Bates SM. Venous thromboembolism in pregnancy: diagnosis, management and prevention. Thromb. Haemost. 101(3), 428-438 (2009).
58. Ho SS, Yu WW, Lao TT, Chow DH, Chung JW, Li Y. Effectiveness of maternity support belts in reducing low back pain during pregnancy: a review. J. Clin. Nurs. 18(11), 1523-1532 (2009).
59. Lindheimer MD, Taler SJ, Cunningham FG; American Society of Hypertension. ASH position paper: hypertension in pregnancy. J. Clin. Hypertens. (Greenwich) 11(4), 214-225 (2009).
60. Wyska E, Jusko WJ. Approaches to pharmacokinetic/pharmacodynamic modeling during pregnancy. Semin. Perinatol. 25(3), 124-132 (2001).
61. Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am. J. Obstet. Gynecol. 192(2), 633-639 (2005).
62. Frederiksen MC. A needed information source. Clin. Pharmacol. Ther. 83(1), 22-23 (2008).
63. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 48(3), 143-157 (2009).
64. Anthony M, Berg MJ. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics and pharmacogenetics: part II - workshop held at the National Institutes of Health, May 4-6, 1999. J. Womens Health 11(8), 617-629 (2002).
65. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin. Drug Metab. Toxicol. 2(6), 947-960 (2006).
66. Mattison D, Zajicek A. Gaps in knowledge in treating pregnant women. Gend. Med. 3(3), 169-182 (2006).
67. Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin. Pharmacol. Ther. 19(1), 68-77 (1976).
68. Philipson A. Pharmacokinetics of antibiotics in pregnancy and labour. Clin. Pharmacokinet. 4(4), 297-309 (1979).
69. Yan R, Fokina V, Hankins GD, Ahmed MS, Nanovskaya TN. The effect of esterases on 17a-hydroxyprogesterone caproate. Am. J. Obstet. Gynecol. 198(2), 229, e221-e225 (2008).
70. Yan R, Nanovskaya TN, Zharikova OL, Mattison DR, Hankins GD, Ahmed MS. Metabolism of 17a-hydroxyprogesterone caproate by hepatic and placental microsomes of human and baboons. Biochem. Pharmacol. 75(9), 1848-1857 (2008).
71. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 27(1), 25-61 (2004).
72. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. 43(8), 487-514 (2004).
73. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br. J. Clin. Pharmacol. 66(2), 179-195 (2008).
74. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. Br. J. Clin. Pharmacol. 65(5), 667-673 (2008).
75. Hytten FE, Leitch I. The Physiology of Human Pregnancy. Blackwell Scientific Publications Ltd, Oxfordshire, UK (1971).
76. Hytten FE. Physiological Adjustments in Pregnancy. WB Saunders, PA, USA (1975).
77. Borg-Stein J, Dugan SA, Gruber J. Musculoskeletal aspects of pregnancy. Am. J. Phys. Med. Rehabil. 84, 180-192 (2005).
78. Fox MW, Harms RW, Davis DH. Selected neurologic complications of pregnancy. Mayo Clin. Proc. 65(12), 1595-1618 (1990).
79. Carlin A, Alfirevic Z. Physiological changes of pregnancy and monitoring. Best Pract. Res. Clin. Obstet. Gynaecol. 22(5), 801-823 (2008).
80. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin. Perinatol. 25(3), 120-123 (2001).
81. Abbas AE, Lester SJ, Connolly H. Pregnancy and the cardiovascular system. Int. J. Cardiol. 98, 179-189 (2005).
82. Lohsiriwat S, Imrittha N. Effect of posture on creatinine clearance in late pregnancy and after pregnancy. J. Obstet. Gynaecol. Res. 34(3), 337-342 (2008).
83. Ganzevoort W, Rep A, Bonsel GJ, de Vries JI, Wolf H. Plasma volume and blood pressure regulation in hypertensive pregnancy. J. Hypertens. 22, 1235-1242 (2004).
84. Qasqas SA, McPherson C, Frishman WH, Elkayam U. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Cardiol. Rev. 12(4), 201-221 (2004).
85. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am. J. Cardiol. 97(8), 1206-1212 (2006).
86. Magee LA, von Dadelszen P. The management of severe hypertension. Semin. Perinatol. 33(3), 138-142 (2009).
87. Hartman-Craven B, Christofides A, O'Connor DL, Zlotkin S. Relative bioavailability of iron and folic acid from a new powdered supplement compared to a traditional tablet in pregnant women. BMC Pregnancy Childbirth 9, 33 (2009).
88. James AH. Venous thromboembolism in pregnancy. Arterioscler. Thromb. Vasc. Biol. 29(3), 326-331 (2009).
89. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis in normal pregnancy. Thromb. Haemost. 52(2), 176-182 (1984).
90. Gibson PS, Powrie R. Anticoagulants and pregnancy: when are they safe? Cleve. Clin. J. Med. 76(2), 113-127 (2009).
91. Clark NP, Delate T, Witt DM, Parker S, McDuffie R. A descriptive evaluation of unfractionated heparin use during pregnancy. J. Thromb. Thrombolysis 27(3), 267-273 (2009).
92. Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am. J. Obstet. Gynecol. 173(4), 1240-1245 (1995).
93. Crowther MA, Spitzer K, Julian J et al. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study. Thromb. Res. 98(2), 133-138 (2000).
94. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am. J. Obstet. Gynecol. 191(3), 1024-1029 (2004).
95. Norris LA, Bonnar J, Smith MP, Steer PJ, Savidge G. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb. Haemost. 92(4), 791-796 (2004).
96. Schatz M, Dombrowski MP, Wise R et al. Spirometry is related to perinatal outcomes in pregnant women with asthma. Am. J. Obstet. Gynecol. 194(1), 120-126 (2006).
97. Jensen D, Duffin J, Lam YM et al. Physiological mechanisms of hyperventilation during human pregnancy. Respir. Physiol. Neurobiol. 161(1), 76-86 (2008).
98. Crapo RO. Normal cardiopulmonary physiology during pregnancy. Clin. Obstet. Gynecol. 39(1), 3-16 (1996).
99. Dombrowski MP. Asthma and pregnancy. Obstet. Gynecol. 108(3 Pt 1), 667-681 (2006).
100. Schatz M. Is maternal asthma a life or death issue for the baby? Thorax 64(2), 93-95 (2009).
101. Schatz M, Dombrowski MP. Clinical practice. Asthma in pregnancy. N. Engl. J. Med. 360(18), 1862-1869 (2009).
102. Tan KS, Thomson NC. Asthma in pregnancy. Am. J. Med. 109(9), 727-733 (2000).
103. Beck SA. Asthma in the female: hormonal effect and pregnancy. Allergy Asthma Proc. 22, 1-4 (2001).
104. Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin. Perinatol. 25(3), 145-152 (2001).
105. Murphy VE, Gibson PG, Talbot PI, Kessell CG, Clifton VL. Asthma self-management skills and the use of asthma education during pregnancy. Eur. Respir. J. 26(3), 435-441 (2005).
106. NHLBI. Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment Update 2004. National Heart Lung and Blood Institute, NIH Publication 05-5236 (2005).
107. Siddiqui S, Goodman N, McKenna S, Goldie M, Waugh J, Brightling CE. Pre-eclampsia is associated with airway hyperresponsiveness. BJOG 115(4), 520-522 (2008).
108. Bakhireva LN, Schatz M, Jones KL, Chambers CD. Asthma control during pregnancy and the risk of preterm delivery or impaired fetal growth. Ann. Allergy Asthma Immunol. 101(2), 137-143 (2008).
109. Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. J. Allergy Clin. Immunol. 121(6), 1379-1384, 1384.e1371 (2008).
110. Lin S, Munsie JP, Herdt-Losavio ML et al. Maternal asthma medication use and the risk of gastroschisis. Am. J. Epidemiol. 168(1), 73-79 (2008).
111. Lin S, Herdt-Losavio M, Gensburg L, Marshall E, Druschel C. Maternal asthma, asthma medication use, and the risk of congenital heart defects. Birth Defects Res. Part A Clin. Mol. Teratol. 85(2), 161-168 (2009).
112. Clifton VL, Rennie N, Murphy VE. Effect of inhaled glucocorticoid treatment on placental 11b-hydroxysteroid dehydrogenase type 2 activity and neonatal birthweight in pregnancies complicated by asthma. Aust. N. Z. J. Obstet. Gynaecol. 46(2), 136-140 (2006).
113. Mayhew TM, Jenkins H, Todd B, Clifton VL. Maternal asthma and placental morphometry: effects of severity, treatment and fetal sex. Placenta 29(4), 366-373 (2008).
114. Ballabh P, Lo ES, Kumari J et al. Pharmacokinetics of betamethasone in twin and singleton pregnancy. Clin. Pharmacol. Ther. 71(1), 39-45 (2002).
115. Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. Drug Saf. 20(4), 361-375 (1999).
116. Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs 63(17), 1813-1820 (2003).
117. Osur SL. The management of asthma and rhinitis during pregnancy. J. Womens Health (Larchmt) 14(3), 263-276 (2005).
118. Yawn B, Knudtson M. Treating asthma and comorbid allergic rhinitis in pregnancy. J. Am. Board Fam. Med. 20(3), 289-298 (2007).
119. Venkata C, Venkateshiah SB. Sleep-disordered breathing during pregnancy. J. Am. Board Fam. Med. 22(2), 158-168 (2009).
120. Hornby PJ, Abrahams TP. Pulmonary pharmacology. Clin. Obstet. Gynecol. 39(1), 17-35 (1996).
121. Fabre E, Tajada M, González de Agüero R et al. Use of drugs in pulmonary medicine in pregnant women. Clin. Pulm. Med. 9(1), 20-32 (2002).
122. Piette V, Daures JP, Demoly P. Treating allergic rhinitis in pregnancy. Curr. Allergy Asthma Rep. 6(3), 232-238 (2006).
123. Garavello W, Somigliana E, Acaia B, Gaini L, Pignataro L, Gaini RM. Nasal lavage in pregnant women with seasonal allergic rhinitis: a randomized study. Int. Arch. Allergy Immunol. 151(2), 137-141 (2009).
124. Chatfield WR, Schramm BM, Richmond WJ. The absorption of ampicillin in late pregnancy and labour. N. Z. Med. J. 80(529), 500-501 (1974).
125. Juon AM, Kühn-Velten WN, Burkhardt T, Krähenmann F, Zimmermann R, von Mandach U. Nifedipine gastrointestinal therapeutic system (GITS) as an alternative to slow-release for tocolysis - tolerance and pharmacokinetic profile. Eur. J. Obstet. Gynecol. Reprod. Biol. 140(1), 27-32 (2008).
126. Silberschmidt AL, Kühn-Velten WN, Juon AM, Zimmermann R, von Mandach U. Nifedipine concentration in maternal and umbilical cord blood after nifedipine gastrointestinal therapeutic system for tocolysis. BJOG 115(4), 480-485 (2008).
127. Bynum TE. Hepatic and gastrointestinal disorders in pregnancy. Med. Clin. North. Am. 61(1), 129-138 (1977).
128. Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. N. Engl. J. Med. 360(24), 2528-2535 (2009).
129. Richter JE. Review article: the management of heartburn in pregnancy. Aliment. Pharmacol. Ther. 22(9), 749-757 (2005).
130. Vlastarakos PV, Manolopoulos L, Ferekidis E, Antsaklis A, Nikolopoulos TP. Treating common problems of the nose and throat in pregnancy: what is safe? Eur. Arch. Otorhinolaryngol. 265(5), 499-508 (2008).
131. Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am. J. Gastroenterol. 104(6), 1541-1545 (2009).
132. Philipson A. Pharmacokinetics of ampicillin during pregnancy. J. Infect. Dis. 136(3), 370-376 (1977).
133. Frederiksen MC, Ruo TI, Chow MJ, Atkinson AJ Jr. Theophylline pharmacokinetics in pregnancy. Clin. Pharmacol. Ther. 40(3), 321-328 (1986).
134. Philipson A. The use of antibiotics in pregnancy. J. Antimicrob. Chemother. 12(2), 101-102 (1983).
135. Philipson A. Plasma levels of ampicillin in pregnant women following administration of ampicillin and pivampicillin. Am. J. Obstet. Gynecol. 130(6), 674-683 (1978).
136. Chamberlain A, White S, Bawdon R, Thomas S, Larsen B. Pharmacokinetics of ampicillin and sulbactam in pregnancy. Am. J. Obstet. Gynecol. 168(2), 667-673 (1993).
137. Bint A, Bullock D, Reeves D, Wilkinson P. A comparative trial of pivmecillinam and ampicillin in bacteriuria of pregnancy. Infection 7(6), 290-293 (1979).
138. Philipson A. Persistance of ampicillin in the intrauterine content following single and multiple doses to pregnant women. Acta Obstet. Gynecol. Scand. 60(2), 121-123 (1981).
139. Pacifici GM. Placental transfer of antibiotics administered to the mother: a review. Int. J. Clin. Pharmacol. Ther. 44(2), 57-63 (2006).
140. Ganapathy V, Prasad PD. Role of transporters in placental transfer of drugs. Toxicol. Appl. Pharmacol. 207(Suppl. 2), 381-387 (2005).
141. Atkinson DE, Brice-Bennett S, D'Souza SW. Antiepileptic medication during pregnancy: does fetal genotype affect outcome? Pediatr. Res. 62(2), 120-127 (2007).
142. Boeuf P, Tan A, Romagosa C et al. Placental hypoxia during placental malaria. J. Infect. Dis. 197(5), 757-765 (2008).
143. Ito S. Transplacental treatment of fetal tachycardia: implications of drug transporting proteins in placenta. Semin. Perinatol. 25(3), 196-201 (2001).
144. Kopecky EA, Simone C, Knie B, Koren G. Transfer of morphine across the human placenta and its interaction with naloxone. Life Sci. 65(22), 2359-2371 (1999).
145. Pastrakuljic A, Schwartz R, Simone C, Derewlany LO, Knie B, Koren G. Transplacental transfer and biotransformation studies of nicotine in the human placental cotyledon perfused in vitro. Life Sci. 63(26), 2333-2342 (1998).
146. Sastry BV, Chance MB, Hemontolor ME, Goddijn-Wessel TA. Formation and retention of cotinine during placental transfer of nicotine in human placental cotyledon. Pharmacology 57(2), 104-116 (1998).
147. Simone C, Byrne BM, Derewlany LO, Oskamp M, Koren G. The transfer, of cocaethylene across the human term placental cotyledon perfused in vitro. Reprod. Toxicol. 11(2-3), 215-219 (1997).
148. Nekhayeva IA, Nanovskaya TN, Deshmukh SV, Zharikova OL, Hankins GD, Ahmed MS. Bidirectional transfer of methadone across human placenta. Biochem. Pharmacol. 69(1), 187-197 (2005).
149. Nanovskaya TN, Nekhayeva IA, Hankins GD, Ahmed MS. Transfer of methadone across the dually perfused preterm human placental lobule. Am. J. Obstet. Gynecol. 198(1), 126.e1-4 (2008).
150. Malek A, Obrist C, Wenzinger S, von Mandach U. The impact of cocaine and heroin on the placental transfer of methadone. Reprod. Biol. Endocrinol. 7, 61-69 (2009).
151. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am. J. Obstet. Gynecol. 185(1), 178-181 (2001).
152. Olivero OA, Parikka R, Poirier MC, Vahakangas K. 30-azido-30- deoxythymidine (AZT) transplacental perfusion kinetics and DNA incorporation in normal human placentas perfused with AZT. Mutat. Res. 428(1-2), 41-47 (1999).
153. Boal JH, Plessinger MA, van den Reydt C, Miller RK. Pharmacokinetic and toxicity studies of AZT (zidovudine) following perfusion of human term placenta for 14 hours. Toxicol. Appl. Pharmacol. 143(1), 13-21 (1997).
154. Gavard L, Gil S, Peytavin G et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am. J. Obstet. Gynecol. 195(1), 296-301 (2006).
155. Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am. J. Obstet. Gynecol. 198(4), 433.e1-2 (2008).
156. Gavard L, Beghin D, Forestier FP et al. Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir. Eur. J. Obstet. Gynecol. Reprod. Biol. 147(2), 157-160 (2009).
157. Heikkinen T, Ekblad U, Laine K. Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. Psychopharmacology (Berl.) 153(4), 450-454 (2001).
158. Casey B, Bawdon RE. Ex vivo human placental transfer of trovafloxacin. Infect. Dis. Obstet. Gynecol. 8(5-6), 228-229 (2000).
159. Polachek H, Holcberg G, Sapir GP et al. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro. Eur. J. Obstet. Gynecol. Reprod. Biol. 122(1), 61-65 (2005).
160. Hnat MD, Gainer J, Bawdon RE, Wendel GD Jr. Transplacental passage of vancomycin in the ex vivo human perfusion model. Infect. Dis. Obstet. Gynecol. 12(2), 57-61 (2004).
161. Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect. Dis. Obstet. Gynecol. 927574 (2008).
162. Holmes HJ, Casey BM, Bawdon RE. Placental transfer of rosiglitazone in the ex vivo human perfusion model. Am. J. Obstet. Gynecol. 195(6), 1715-1719 (2006).
163. Ray JG, Boskovic R, Knie B, Hard M, Portnoi G, Koren G. In vitro analysis of human transplacental transport of desmopressin. Clin. Biochem. 37(1), 10-13 (2004).
164. Nanovskaya TN, Nekhayeva I, Hankins GD, Ahmed MS. Effect of human serum albumin on transplacental transfer of glyburide. Biochem. Pharmacol. 72(5), 632-639 (2006).
165. Pollex E, Lubetsky A, Koren G. The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta. Placenta 29(8), 743-747 (2008).
166. Kovo M, Haroutiunian S, Feldman N, Hoffman A, Glezerman M. Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur. J. Obstet. Gynecol. Reprod. Biol. 136(1), 29-33 (2008).
167. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 26(5), 1390-1394 (2003).
168. Holcberg G, Tsadkin-Tamir M, Sapir OP et al. Transfer of insulin lispro across the human placenta. Eur. J. Obstet. Gynecol. Reprod. Biol. 115(1), 117-118 (2004).
169. la-Kokko TI, Pienimaki P, Herva R, Hollmen AI, Pelkonen O, Vahakangas K. Transfer of lidocaine and bupivacaine across the isolated perfused human placenta. Pharmacol. Toxicol. 77(2), 142-148 (1995).
170. Herman NL, Li AT, Van Decar TK et al. Transfer of methohexital across the perfused human placenta. J. Clin. Anesth. 12(1), 25-30 (2000).
171. Johnson RF, Cahana A, Olenick MP et al. A comparison of the placental transfer of ropivacaine versus bupivacaine. Anesth. Analg. 89(3), 703-708 (1999).
172. Giroux M, Teixera MG, Dumas JC, Desprats R, Grandjean H, Houin G. Influence of maternal blood flow on the placental transfer of three opioids - fentanyl, alfentanil, sufentanil. Biol. Neonate 72(3), 133-141 (1997).
173. Pienimaki P, Lampela E, Hakkola J, Arvela P, Raunio H, Vahakangas K. Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta. Epilepsia 38(3), 309-316 (1997).
174. Myllynen PK, Pienimaki PK, Vahakangas KH. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur. J. Clin. Pharmacol. 58(10), 677-682 (2003).
175. Magee KP, Bawdon RE. Ex vivo human placental transfer and the vasoactive properties of hydralazine. Am. J. Obstet. Gynecol. 182(1), 167-169 (2000).
176. Mortimer RH, Cannell GR, Addison RS, Johnson LP, Roberts MS, Bernus I. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J. Clin. Endocrinol. Metab. 82(9), 3099-3102 (1997).
177. Schmolling J, Jung S, Reinsberg J, Schlebusch H. Diffusion characteristics of placental preparations affect the digoxin passage across the isolated placental lobule. Ther. Drug Monit. 19(1), 11-16 (1997).
178. Mose T, Knudsen LE, Hedegaard M, Mortensen GK. Transplacental transfer of monomethyl phthalate and mono(2-ethylhexyl) phthalate in a human placenta perfusion system. Int. J. Toxicol. 26(3), 221-229 (2007).
179. Myren M, Mose T, Mathiesen L, Knudsen LE. The human placenta - an alternative for studying foetal exposure. Toxicol. In Vitro. 21, 1332-1340 (2007).
180. Fox H. A contemporary view of the human placenta. Midwifery 7, 31-39 (1991).
181. van der Aa EM, Peereboom-Stegeman JH, Noordhoek J, Gribnau FW, Russel FG. Mechanisms of drug transfer across the human placenta. Pharm. World Sci. 20, 139-148 (1998).
182. Kaufmann P, Frank HG. Placental development. In: Fetal and Neonatal Physiology. Polin RA, Fox WW, Abman SH (Eds). Saunders, London, UK, 85-97 (2004).
183. Simone C, Derewlany LO, Koren G. Drug transfer across the placenta. Considerations in treatment and research. Clin. Perinatol. 21, 463-481 (1994).
184. Ganapathy V, Prasad PD, Ganapathy ME, Leibach FH. Placental transporters relevant to drug distribution across the maternal-fetal interface. J. Pharmacol. Exp. Ther. 294, 413-420 (2000).
185. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am. J Gastroenterol. 104, 228-233 (2009).
186. Bawdon RE, Kaul S, Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol. Obstet. Invest. 38(1), 1-4 (1994).
187. Gilstrap LC, Bawdon RE, Roberts SW, Sobhi S. The transfer of the nucleoside analog ganciclovir across the perfused human placenta. Am. J. Obstet. Gynecol. 170(4), 967-972 (1994).
188. Pienimäki P, Hartikainen AL, Arvela P et al. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 36(3), 241-248 (1995).
189. Malek A, Blann E, Mattison DR. Human placental transport of oxytocin. J. Matern. Fetal Med. 5(5), 245-255 (1996).
190. Bawdon RE. Ex vivo human placental transfer of anti-human immunodeficiency virus compounds. Infect. Dis. Obstet. Gynecol. 5(4), 310-315 (1997).
191. Bloom SL, Dias KM, Bawdon RE, Gilstrap LC 3rd. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am. J. Obstet. Gynecol. 176(2), 291-293 (1997).
192. Peytavin G, Leng JJ, Forestier F, Saux M, Hohlfeld P, Farinotti R. Placental transfer of pyrimethamine studied in an ex vivo placental perfusion model. Biol. Neonate 78(2), 83-85 (2000).
193. Gavard L, Gil S, Peytavin G et al. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am. J. Obstet. Gynecol. 195(1), 296-301 (2006).
194. Hewitt M, Madden JC, Rowe PH, Cronin MT. Structure-based modelling in reproductive toxicology: (Q)SARs for the placental barrier. SAR QSAR Environ. Res. 18(1-2), 57-76 (2007).
195. He YL, Seno H, Sasaki K, Tashiro C. The influences of maternal albumin concentrations on the placental transfer of propofol in human dually perfused cotyledon in vitro. Anesth. Analg. 94(5), 1312-1314 (2002).
196. Nanovskaya TN, Patrikeeva S, Hemauer S et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J. Matern. Fetal Neonatal Med. 21(3), 197-207 (2008).
197. Gulati A, Boudinot FD, Gerk PM. Binding of lopinavir to human a1-acid glycoprotein and serum albumin. Drug Metab. Dispos. 37(8), 1572-1575 (2009).
198. Schrier RW, Cadnapaphornchai MA, Ohara M. Water retention and aquaporins in heart failure, liver disease and pregnancy. J. R. Soc. Med. 94(6), 265-269 (2001).
199. Riquelme G. Placental chloride channels: a review. Placenta 30(8), 659-669 (2009).
200. Illsley NP. Glucose transporters in the human placenta. Placenta 21(1), 14-22 (2000).
201. Kovo M, Kogman N, Ovadia O, Nakash I, Golan A, Hoffman A. Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat. Diagn. 28(6), 544-548 (2008).
202. Cleal JK, Lewis RM. The mechanisms and regulation of placental amino acid transport to the human foetus. J. Neuroendocrinol. 20(4), 419-426 (2008).
203. Grillo MA, Lanza A, Colombatto S. Transport of amino acids through the placenta and their role. Amino Acids 34(4), 517-523 (2008).
204. Unadkat JD, Dahlin A, Vijay S. Placental drug transporters. Curr. Drug Metab. 5(1), 125-131 (2004).
205. Cetin I, Alvino G. Intrauterine growth restriction: implications for placental metabolism and transport. A review. Placenta 30(Suppl. A), S77-S82 (2009).
206. Jansson T, Myatt L, Powell TL. The role of trophoblast nutrient and ion transporters in the development of pregnancy complications and adult disease. Curr. Vasc. Pharmacol. 7(4), 521-533 (2009).
207. Brambell FW, Halliday R, Brierley J, Hemmings WA. Transference of passive immunity from mother to young. Lancet 266, 964-965 (1954).
208. Leach JL, Sedmak DD, Osborne JM et al. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. J. Immunol. 157, 3317-3322 (1996).
209. Kim J, Mohanty S, Ganesan LP et al. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J. Immunol. 182, 2583-2589 (2009).
210. MacDonald NE, Riley LE, Steinhoff MC. Influenza immunization in pregnancy. Obstet. Gynecol. 114(2 Pt 1), 365-368 (2009).
211. Potter RC, Gonik B. Prevention of influenza in mothers and infants. Expert Rev. Vaccines 8(2), 149-152 (2009).
212. Skowronski DM, De Serres G. Is routine influenza immunization warranted in early pregnancy? Vaccine 27(35), 4754-4770 (2009).
213. Vahakangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br. J. Pharmacol. 158(3), 665-678 (2009).
214. Carter AM. Placental oxygen consumption, part I: in vivo studies. Placenta 21(Suppl. A), 31-37 (2000).
215. Schneider H. Placental oxygen consumption, part II: in vitro studies - a review. Placenta 21(Suppl. A), S38-S44 (2000).
216. Schneider H. Tolerance of human placental tissue to severe hypoxia and its relevance for dual ex vivo perfusion. Placenta 30(Suppl. A), S71-S76 (2009).
217. Murer H, Kinne R. The use of isolated membrane vesicles to study epithelial transport processes. J. Membr. Biol. 55, 81-95 (1980).
218. Bissonnette JM. Membrane vesicles from trophoblast cells as models for placental exchange studies. Placenta 3, 99-106 (1982).
219. Baumann MU, Deborde S, Illsley NP. Placental glucose transfer and fetal growth. Endocrine 19(1), 13-22 (2002).
220. Ushigome F, Koyabu N, Satoh S et al. Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharm. Res. 20(1), 38-44 (2003).
221. Hemmings DG, Lowen B, Sherburne R, Sawicki G, Guilbert LJ. Villous trophoblasts cultured on semi-permeable membranes form an effective barrier to the passage of high and low molecular weight particles. Placenta 22, 70-79 (2001).
222. Sullivan MHF. Endocrine cell lines from the placenta. Mol. Cell. Endocrinol. 228, 109-119 (2002).
223. Miller RK, Genbacev O, Turner MA, Aplin JD, Caniggia I, Huppertz B. Human placental explants in culture: approaches and assessments. Placenta 26, 439-448 (2005).
224. Polliotti BM, Abramowsky C, Schwartz DA et al. Culture of first-trimester and full-term human chorionic villus explants: role of human chorionic gonadotropin and human placental lactogen as a viability index. Early Pregnancy 1, 270-280 (1995).
225. Palmer ME, Watson AL, Burton GJ. Morphological analysis of degeneration and regeneration of syncytitrophoblast in first trimester placental villi during organ culture. Hum. Reprod. 12, 379-382 (1997).
226. Siman CM, Sibley CP, Jones CJP, Turner MA, Greenwood SL. The functional regeneration of syncytiotrophoblast in cultured explants of term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R1116 (2001).
227. Sooranna SR, Oteng-Ntim E, Meah R, Ryder TA, Bajoria R. Characterization of human placental explants morphological, biochemical and physiological studies using first and third trimester placenta. Hum. Reprod. 14, 536-541 (1999).
228. Cedard L, Yannotti S, Varangot J. The perfusion of the placenta in vitro used in the study of the biosynthesis of estrogens. C. R. Seances Soc. Biol. Fil. 155, 458-461 (1961).
229. Klinge E, Mattila MJ, Penttila O, Jukarainen E. Influence of drugs on vasoactive peptides and amines in perfused human placenta. Ann. Med. Exp. Biol. Fenn. 44, 369-375 (1966).
230. Hensleigh PA, Krantz KE. Extracorporeal perfusion of the human placenta. I. Placental transfer of ascorbic acid. Am. J. Obstet. Gynecol. 96, 5-13 (1966).
231. Panigel M, Pascaud M, Brun JL. Radioangiographic study of circulation in the villi and intervillous space of isolated human placental cotyledon kept viable by perfusion. J. Physiol. (Paris) 59, 277 (1967).
232. Nesbitt RE Jr, Rice PA, Rourke JE, Torresi VF, Souchay AM. In vitro perfusion studies of the human placenta. A newly-designed apparatus for extracorporeal perfusion achieving dual closed circulation. Gynecol. Invest. 1, 185-203 (1970).
233. Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium and leucine. Am. J. Obstet. Gynecol. 114, 822-828 (1972).
234. Miller RK, Wier PJ, Maulik D, di Sant'Agnese PA. Human placenta in vitro: characterization during 12 h of dual perfusion. Contrib. Gynecol. Obstet. 13, 77-84 (1985).
235. Malek A, Leiser R. Influence of the magnesium aspartate hydrochloride administration to the maternal circuit on the aspartate concentration of the fetal circuit under in vitro perfusion of human placenta. Eur. J. Obstet. Gynecol. Reprod. Biol. 142(1), 12-17 (2009).
236. Rahi MM, Heikkinen TM, Hakala KE, Laine KP. The effect of probenecid and MK-571 on the feto-maternal transfer of saquinavir in dually perfused human term placenta. Eur. J. Pharm. Sci. 37(5), 588-592 (2009).
237. Shintaku K, Hori S, Tsujimoto M et al. Transplacental pharmacokinetics of diclofenac in perfused human placenta. Drug Metab. Dispos. 37(5), 962-968 (2009).
238. Earhart AD, Patrikeeva S, Wang X et al. Transplacental transfer and metabolism of bupropion. J. Matern. Fetal Neonatal Med. 1-10 (2009).
239. Bajoria R, Fisk NM. Permeability of human placenta and fetal membranes to thyrotropin-stimulating hormone in vitro. Pediatr. Res. 43, 621-628 (1998).
240. Schneider H, Dancis J. In vitro human placental perfusion of human placenta. Trophoblast Res. 2, 597-605 (1987).
241. Schmolling J, Brunken M, Richter O, Ulrich U, Schmidt S, Krebs D. Photoradiation of perfused placental tissue - a suitable in vitro model for photodynamic therapy? Arch. Gynecol. Obstet. 265, 199-203 (2001).
242. Juric S, Newport DJ, Ritchie JC, Galanti M, Stowe ZN. Zolpidem (Ambien®) in pregnancy: placental passage and outcome. Arch. Womens Ment. Health 12(6), 441-446 (2009).
243. Muller AE, Oostvogel PM, DeJongh J et al. Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera. Antimicrob. Agents Chemother. 53(4), 1574-1580 (2009).
244. Whyatt RM, Garfinkel R, Hoepner LA et al. A biomarker validation study of prenatal chlorpyrifos exposure within an inner-city cohort during pregnancy. Environ. Health Perspect. 117(4), 559-567 (2009).
245. Sastry BV. Techniques to study human placental transport. Adv. Drug. Deliv. Rev. 38, 17-39 (1999).
246. Aitken RJ, Chaudhry MQ, Boxall AB, Hull M. Manufacture and use of nanomaterials: current status in the UK and global trends. Occup. Med. (Lond.) 56, 300-306 (2006).
247. Maynard AD. Nanotechnology: the next big thing, or much ado about nothing? Ann. Occup. Hyg. 51, 1-12 (2007).
248. Oberdörster G, Maynard A, Donaldson K et al. Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part. Fibre Toxicol. 2, 8 (2005).
249. Seaton A, Tran L, Aitken R, Donaldson K. Nanoparticles, human health hazard and regulation. J. R. Soc. Interface 7(Suppl. 1), S119-S129 (2010).
250. Semmler-Behnke M, Fertsch S, Schmid G, Wenk A, Kreyling W. Uptake of 1.4 nm versus 18 nm gold particles by secondary target organs is size dependent in control and pregnant rats after intratracheal or intravenous application. Presented at: EuroNanoForum 2007. European Commission, Düsseldorf, Germany, 19-21 June 2007.
251. Takeda K, Suzuki K, Ishihara A et al. Nanoparticles transferred from pregnant mice to their offspring can damage the genital and cranial nerve systems. J. Health Sci. 55, 95-102 (2009).
252. Chu M, Wu Q, Yang H et al. Transfer of quantum dots from pregnant mice to pups across the placental barrier. Small 6, 670-678 (2010).
253. Myllynen PK, Loughran MJ, Howard CV, Sormunen R, Walsh AA, Vahakangas KH. Kinetics of gold nanoparticles in the human placenta. Reprod. Toxicol. 26, 130-137 (2008).
254. Wick P, Malek A, Manser P et al. Barrier capacity of human placenta for nanosized materials. Environ. Health Perspect. 118, 432-436 (2010).
255. Caton AR, Bell EM, Druschel CM et al. Maternal hypertension, antihypertensive medication use, and the risk of severe hypospadias. Birth Defects Res. Part A Clin. Mol. Teratol. 82(1), 34-40 (2008).
256. Lowe SA, Brown MA, Dekker GA et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust. NZ J. Obstet. Gynaecol. 49(3), 242-246 (2009).
257. Magee LA, Abalos E, von Dadelszen P, Sibai B, Walkinshaw SA. Control of hypertension in pregnancy. Curr. Hypertens. Rep. 11(6), 429-436 (2009).
258. Coppage KH, Sibai BM. Treatment of hypertensive complications in pregnancy. Curr. Pharm. Des. 11(6), 749-757 (2005).
259. Tabacova SA, Kimmel CA. Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. Reprod. Toxicol. 15(5), 467-478 (2001).
260. Gersak K, Cvijic M, Cerar LK. Angiotensin II receptor blockers in pregnancy: a report of five cases. Reprod. Toxicol. 28(1), 109-112 (2009).
261. James AH, Abel DE, Brancazio LR. Anticoagulants in pregnancy. Obstet. Gynecol. Surv. 61, 59-69 (2006).
262. James AH. Pregnancy-associated thrombosis. Hematology Am. Soc. Hematol. Educ. Program 277-285 (2009).
263. Hawkins D, Evans J. Minimising the risk of heparin-induced osteoporosis during pregnancy. Expert Opin. Drug Saf. 4(3), 583-590 (2005).
264. Santoro R, Iannaccaro P, Prejanò S et al. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy. Blood Coagul. Fibrinolysis 20(4), 240-243 (2009).
265. Lebaudy C, Hulot JS, Amoura Z et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin. Pharmacol. Ther. 84(3), 370-377 (2008).
266. Patel JP, Hunt BJ. Where do we go now with low molecular weight heparin use in obstetric care? J. Thromb. Haemost. 6(9), 1461-1467 (2008).
267. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 181(1-2), 55-58 (2009).
268. Jamieson DJ, Honein MA, Rasmussen SA et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet 374(9688), 451-458 (2009).
269. Rasmussen SA, Jamieson DJ, Macfarlane K et al. Pandemic influenza and pregnant women: summary of a meeting of experts. Am. J. Public Health 99(Suppl. 2), S248-S254 (2009).
270. Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro. Surveill. 14(33), 19309 (2009).
271. Goodnight WH, Soper DE. Pneumonia in pregnancy. Crit. Care Med. 33(10 Suppl.), S390-S397 (2005).
272. Trinh QD, Izumi Y, Komine-Aizawa S et al. H3N2 influenza A virus replicates in immortalized human first trimester trophoblast cell lines and induces their rapid apoptosis. Am. J. Reprod. Immunol. 62(3), 139-146 (2009).
273. Tong A, Biringer A, Ofner-Agostini M, Upshur R, McGeer A. A cross-sectional study of maternity care providers' and women's knowledge, attitudes, and behaviours towards influenza vaccination during pregnancy. J. Obstet. Gynaecol. Can. 30(5), 404-410 (2008).
274. Zaman K, Roy E, Arifeen SE et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl J. Med. 359(15), 1555-1564 (2008).
275. Granwehr BP. Influenza immunisation during pregnancy reduced influenza in infants and respiratory illness in mothers. Evid. Based Med. 14(2), 55 (2009).
276. Power ML, Leddy MA, Anderson BL, Gall SA, Gonik B, Schulkin J. Obstetrician-gynecologists' practices and perceived knowledge regarding immunization. Am. J. Prev. Med. 37(3), 231-234 (2009).
277. Wutzler P, Schmidt-Ott R, Hoyer H, Sauerbrei A. Prevalence of influenza A and B antibodies in pregnant women and their offspring. J. Clin. Virol. 46(2), 161-164 (2009).
278. Marx H, Amin P, Lazarus JH. Hyperthyroidism and pregnancy. Br. Med. J. 336(7645), 663-667 (2008).
279. Mandel SJ, Cooper DS. The use of antithyroid drugs in pregnancy and lactation. J. Clin. Endocrinol. Metab. 86(6), 2354-2359 (2001).
280. Browne ML, Rasmussen SA, Hoyt AT et al. Maternal thyroid disease, thyroid medication use, and selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res. Part A Clin. Mol. Teratol. 85(7), 621-628 (2009).
281. Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, Mimura T. Maternal hyperthyroidism and congenital malformation in the offspring. Clin. Endocrinol. (Oxf.) 20(6), 695-700 (1984).
282. Chan GW, Mandel SJ. Therapy insight: management of Graves' disease during pregnancy. Nat. Clin. Pract. Endocrinol. Metab. 3(6), 470-478 (2007).
283. Abalovich M, Amino N, Barbour LA. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 92(Suppl. 8), S1-S47 (2007).
284. Okosieme OE, Marx H, Lazarus JH. Medical management of thyroid dysfunction in pregnancy and the postpartum. Expert Opin. Pharmacother. 9(13), 2281-2293 (2008).
285. Bach-Huynh T-G, Jonklaas J. Thyroid medications during pregnancy. Ther. Drug Monit. 28, 431-441 (2006).
286. Clark SM, Saade GR, Snodgrass WR, Hankins GD. Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. Ther. Drug Monit. 28(4), 477-483 (2006).
287. Lagerberg RE. Malaria in pregnancy: a literature review. J. Midwifery Womens Health 53(3), 209-215 (2008).
288. Omo-Aghoja LO, Abe E, Feyi-Waboso P, Okonofua FE. The challenges of diagnosis and treatment of malaria in pregnancy in low resource settings. Acta Obstet. Gynecol. Scand. 87(7), 693-696 (2008).
289. Tomson T, Battino D. Pregnancy and epilepsy: what should we tell our patients? J. Neurol. 256, 856-862 (2009).
290. Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 50, 2163-2166 (2009).
291. Meador KJ, Baker GA, Browning N et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N. Engl. J. Med. 360, 1597-1605 (2009).
292. Tarning J, McGready R, Lindegardh N et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53, 3837-3846 (2009).
293. McKoy JM, Bennett CL, Scheetz MH et al. Hepatotoxicity associated with long-versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Drug Saf. 32, 147-155 (2009).
294. New Medicines Database http://newmeds.phrma.org/index.php?indi cation=941&drug=&company=&status (Accessed 4 January 2010)
295. US FDA news release, 30 December 2009 www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2009/ucm195934. htm (Accessed 4 January 2010)
296. ATC classifications www.fmrc.org.au/atc/ (Accessed 4 January 2010)